Vahdat, Linda T

Publications

Sort by

Co-Author Network

selected publications

Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer. Cell reports. 2020 Academic Article GET IT
Times cited: 3
Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer. BMC cancer. 2019 Academic Article GET IT
Times cited: 1
Clinical benefit, toxicity and cost of metastatic breast cancer therapies: systematic review and meta-analysis. Breast cancer research and treatment. 2019 Review GET IT
Times cited: 3
Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study. Breast cancer research : BCR. 2019 Academic Article GET IT
Times cited: 15
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. The New England journal of medicine. 2019 Academic Article GET IT
Times cited: 89
Personalized Nutrition in Disrupting Cancer - Proceedings From the 2017 American College of Nutrition Annual Meeting. Journal of the American College of Nutrition. 2018 Academic Article GET IT
Times cited: 6
Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 12
Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. The Lancet. Oncology. 2018 Academic Article GET IT
Times cited: 41
Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 40
An Integrated Systems Biology Approach Identifies TRIM25 as a Key Determinant of Breast Cancer Metastasis. Cell reports. 2017 Academic Article GET IT
Times cited: 34
Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. Cancer. 2017 Academic Article GET IT
Times cited: 44
Sacituzumab govitecan: an antibody-drug conjugate. Expert opinion on biological therapy. 2017 Academic Article GET IT
Times cited: 7
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 45
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Academic Article GET IT
Times cited: 98
Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer. The oncologist. 2017 Academic Article GET IT
Times cited: 8
Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study. Breast cancer (Dove Medical Press). 2016 Academic Article GET IT
Glutamine for the treatment of vincristine-induced neuropathy in children and adolescents with cancer. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2016 Academic Article GET IT
Times cited: 20
Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 53
Smart Nanotransformers with Unique Enzyme-Inducible Structural Changes and Drug Release Properties. Biomacromolecules. 2016 Academic Article GET IT
Times cited: 9
Activation of Hematopoietic Stem/Progenitor Cells Promotes Immunosuppression Within the Pre-metastatic Niche. Cancer research. 2015 Academic Article GET IT
Times cited: 53
Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 2015 Academic Article GET IT
Times cited: 930
Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies. SpringerPlus. 2015 Academic Article GET IT
Times cited: 9
Obesity-dependent changes in interstitial ECM mechanics promote breast tumorigenesis. Science translational medicine. 2015 Academic Article GET IT
Times cited: 109
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 94
Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity. BMC cancer. 2015 Academic Article GET IT
Times cited: 37
EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 92
Menopause is a determinant of breast adipose inflammation. Cancer prevention research (Philadelphia, Pa.). 2015 Academic Article GET IT
Times cited: 51
Efficacy of Scalp Cooling in Preventing Chemotherapy-Induced Alopecia in Breast Cancer Patients Receiving Adjuvant Docetaxel and Cyclophosphamide Chemotherapy. Clinical breast cancer. 2015 Academic Article GET IT
Times cited: 24
Erratum to: Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast cancer research and treatment. 2015 Article GET IT
Times cited: 1
Disease-free survival according to the use of postmastectomy radiation therapy after neoadjuvant chemotherapy. Clinical breast cancer. 2014 Academic Article GET IT
Times cited: 9
Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast cancer research and treatment. 2014 Academic Article GET IT
Times cited: 118
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Academic Article GET IT
Times cited: 55
Ixabepilone-induced mitochondria and sensory axon loss in breast cancer patients. Annals of clinical and translational neurology. 2014 Academic Article GET IT
Times cited: 20
Remodeling of the methylation landscape in breast cancer metastasis. PloS one. 2014 Academic Article GET IT
Times cited: 21
Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer. Clinical breast cancer. 2014 Academic Article GET IT
Times cited: 40
Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer. Breast cancer research and treatment. 2014 Academic Article GET IT
Times cited: 38
Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer. The oncologist. 2014 Academic Article GET IT
Times cited: 29
Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device. Lab on a chip. 2013 Academic Article GET IT
Times cited: 66
Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma. Breast cancer research and treatment. 2013 Academic Article GET IT
Times cited: 12
Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer. Journal of geriatric oncology. 2013 Academic Article GET IT
Times cited: 7
Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy. Breast cancer research and treatment. 2013 Academic Article GET IT
Times cited: 39
BreastPRS is a gene expression assay that stratifies intermediate-risk Oncotype DX patients into high- or low-risk for disease recurrence. Breast cancer research and treatment. 2013 Academic Article GET IT
Times cited: 6
High-grade KIT-negative sarcoma of the small bowel in a patient with chronic myeloid leukemia receiving long-term tyrosine kinase inhibitors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Academic Article GET IT
Times cited: 1
Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse. Annals of oncology : official journal of the European Society for Medical Oncology. 2013 Academic Article GET IT
Times cited: 49
Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 29
Suppression of miRNA-708 by polycomb group promotes metastases by calcium-induced cell migration. Cancer cell. 2013 Academic Article GET IT
Times cited: 109
Novel data in metastatic breast cancer. Clinical advances in hematology & oncology : H&O. 2013 Academic Article GET IT
Times cited: 2
Breast cancer subtypes in Asian-Americans differ according to Asian ethnic group. Journal of immigrant and minority health. 2012 Academic Article GET IT
Times cited: 16
Microenvironmental regulation of epithelial-mesenchymal transitions in cancer. Cancer research. 2012 Review GET IT
Times cited: 217
Employment after a breast cancer diagnosis: a qualitative study of ethnically diverse urban women. Journal of community health. 2012 Academic Article GET IT
Times cited: 33
Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials. Clinical breast cancer. 2012 Academic Article GET IT
Times cited: 9
Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2012 Academic Article GET IT
Times cited: 20
Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition. Cancer research. 2012 Academic Article GET IT
Times cited: 164
The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer. Expert opinion on biological therapy. 2012 Academic Article GET IT
Times cited: 26
Incremental increase in VEGFR1⁺ hematopoietic progenitor cells and VEGFR2⁺ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients. Breast cancer research and treatment. 2011 Academic Article GET IT
Times cited: 21
Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies. Breast (Edinburgh, Scotland). 2011 Academic Article GET IT
Times cited: 9
Eribulin mesylate. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Review GET IT
Times cited: 47
Novel treatment options in the management of metastatic breast cancer. Clinical advances in hematology & oncology : H&O. 2011 Review GET IT
Times cited: 2
Survival in metastatic breast cancer. Clinical Advances in Hematology and Oncology. 2011 Article
Breast cancer methylomes establish an epigenomic foundation for metastasis. Science translational medicine. 2011 Academic Article GET IT
Times cited: 199
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet (London, England). 2011 Academic Article GET IT
Times cited: 708
Treatment of metastatic breast cancer: second line and beyond. Annals of oncology : official journal of the European Society for Medical Oncology. 2010 Review GET IT
Times cited: 65
Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy. Breast cancer research and treatment. 2010 Academic Article GET IT
Times cited: 17
Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 162
Eribulin mesylate for the treatment of breast cancer. Expert opinion on pharmacotherapy. 2010 Review GET IT
Times cited: 19
Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast cancer research and treatment. 2010 Academic Article GET IT
Times cited: 60
The effect of a contemplative self-healing program on quality of life in women with breast and gynecologic cancers. Alternative therapies in health and medicine. 2010 Academic Article GET IT
Times cited: 24
Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clinical breast cancer. 2010 Article GET IT
Times cited: 92
Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary. Annals of oncology : official journal of the European Society for Medical Oncology. 2010 Academic Article GET IT
Times cited: 8
Novel combinations for the treatment of metastatic breast cancer. Cancers. 2010 Review GET IT
Times cited: 1
Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Conference Paper GET IT
Times cited: 100
Angiomodulin is a specific marker of vasculature and regulates vascular endothelial growth factor-A-dependent neoangiogenesis. Circulation research. 2009 Academic Article GET IT
Times cited: 24
Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. Biochimica et biophysica acta. 2009 Review GET IT
Times cited: 134
Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Academic Article GET IT
Times cited: 53
Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 200
Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205. Annals of oncology : official journal of the European Society for Medical Oncology. 2009 Academic Article GET IT
Times cited: 28
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 94
Integrating epothilones into the treatment of patients with metastatic breast cancer: clinical perspectives on incorporating recent data in the practice setting. Clinical breast cancer. 2008 Academic Article GET IT
Times cited: 4
Choosing a taxane for adjuvant treatment of breast cancer: more than a flip of the coin?. Nature clinical practice. Oncology. 2008 Article GET IT
Times cited: 3
Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer. Clinical breast cancer. 2008 Academic Article GET IT
Times cited: 57
Epothilones: clinical update and future directions. Oncology (Williston Park, N.Y.). 2008 Review GET IT
Times cited: 19
Clinical studies with epothilones for the treatment of metastatic breast cancer. Seminars in oncology. 2008 Academic Article GET IT
Times cited: 9
Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms. The oncologist. 2008 Review GET IT
Times cited: 45
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Conference Paper GET IT
Times cited: 66
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 459
Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 143
Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 313
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 201
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 260
Randomized trial of low-dose interleukin-2 vs cyclosporine A and interferon-gamma after high-dose chemotherapy with peripheral blood progenitor support in women with high-risk primary breast cancer. Bone marrow transplantation. 2007 Academic Article GET IT
Times cited: 7
Microtubule-Stabilizing Agent: Halichondrin B Analog (E7389). Breast Diseases. 2007 Article GET IT
The presentation of contralateral axillary lymph node metastases from breast carcinoma: a clinical management dilemma. The breast journal. 2007 Academic Article GET IT
Times cited: 28
Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer. Breast cancer research and treatment. 2007 Academic Article GET IT
Times cited: 81
Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: case reports and review of the literature. Breast cancer research and treatment. 2007 Review GET IT
Times cited: 17
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Academic Article GET IT
Times cited: 97
Measuring the impact of chemotherapy on fertility in women with breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Letter GET IT
Times cited: 61
Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Academic Article GET IT
Times cited: 42
Dermatological toxicity of ixabepilone. Anticancer research. 2006 Academic Article GET IT
Times cited: 5
Phase I/II study of tandem cycles of high-dose chemotherapy followed by autologous hematopoietic stem cell support in women with advanced ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2006 Academic Article GET IT
Times cited: 6
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Conference Paper GET IT
Times cited: 83
Pilot study of tandem high-dose chemotherapy and autologous stem cell transplantation with a novel combination of regimens in patients with poor risk lymphoma. Bone marrow transplantation. 2005 Academic Article GET IT
Times cited: 5
Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study. Clinical oncology (Royal College of Radiologists (Great Britain)). 2005 Academic Article GET IT
Times cited: 76
Cytokine genotype polymorphisms in breast carcinoma: associations of TGF-beta1 with relapse. Cancer investigation. 2005 Academic Article GET IT
Times cited: 28
Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2004 Review GET IT
Times cited: 120
Prevention of chemotherapy and radiation toxicity with glutamine. Cancer treatment reviews. 2003 Review GET IT
Times cited: 177
A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma. Cancer. 2003 Academic Article GET IT
Times cited: 12
Therapy-related myelodysplastic syndrome after autologous stem cell transplantation for breast cancer. Leukemia. 2002 Academic Article GET IT
Times cited: 14
Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer. Bone marrow transplantation. 2002 Academic Article GET IT
Times cited: 9
Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 322
Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clinical cancer research : an official journal of the American Association for Cancer Research. 2001 Academic Article GET IT
Times cited: 131
The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. Cancer chemotherapy and pharmacology. 2001 Academic Article GET IT
Times cited: 16
Bilateral facial nerve palsy secondary to the administration of high-dose paclitaxel. Annals of oncology : official journal of the European Society for Medical Oncology. 1999 Academic Article GET IT
Times cited: 13
A phase I study of high-dose BCNU, etoposide and escalating-dose thiotepa (BTE) with hematopoietic progenitor cell support in adults with recurrent and high-risk brain tumors. Journal of neuro-oncology. 1999 Academic Article GET IT
Times cited: 8
CD34+ cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer. Journal of hematotherapy & stem cell research. 1999 Academic Article GET IT
Times cited: 5
High-dose thiotepa and etoposide-based regimens with autologous hematopoietic support for high-risk or recurrent CNS tumors in children and adults. Bone marrow transplantation. 1998 Academic Article GET IT
Times cited: 19
Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 1998 Academic Article GET IT
Times cited: 24
Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Academic Article GET IT
High-dose chemotherapy with autologous stem cell support for breast cancer. Current opinion in hematology. 1997 Review GET IT
Times cited: 11
Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support. Journal of hematotherapy. 1997 Academic Article GET IT
Times cited: 28
Systemic adjuvant therapy of breast cancer. Journal of surgical oncology. 1997 Review GET IT
Times cited: 13
Comparative analysis of breast cancer contamination in mobilized and nonmobilized hematopoietic grafts. Journal of hematotherapy. 1996 Review GET IT
Times cited: 16
Rapidly cycled courses of high-dose alkylating agents supported by filgrastim and peripheral blood progenitor cells in patients with metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 1995 Academic Article GET IT
Times cited: 18
High-dose therapy for breast cancer. Blood reviews. 1995 Academic Article GET IT
Times cited: 11
Carboplatin and etoposide in metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 1995 Letter GET IT
Times cited: 2
High-dose chemotherapy of breast cancer: current status and developmental strategies. European journal of cancer. 1995 Conference Paper GET IT
Times cited: 5
High-dose chemotherapy of metastatic breast cancer: a review. Cancer investigation. 1995 Review GET IT
Times cited: 4
Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood. 1994 Academic Article GET IT
Times cited: 248
Factors affecting the mobilization of primitive and committed hematopoietic progenitors into the peripheral blood of cancer patients. Bone marrow transplantation. 1994 Academic Article GET IT
Times cited: 21
Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia. Blood. 1994 Academic Article GET IT
Times cited: 73
High-intensity chemotherapy with peripheral blood progenitor cell support. Seminars in oncology. 1994 Conference Paper GET IT
Times cited: 13
High-intensity chemotherapy with hematopoietic support in breast cancer. Annals of the New York Academy of Sciences. 1993 Academic Article GET IT
Times cited: 5
Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1993 Academic Article GET IT
Times cited: 65
[Four additional cases of aplastic anemia following chloramphenicol therapy]. Schweizerische medizinische Wochenschrift. 1969 Academic Article GET IT
Times cited: 4

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

The Role of Histone H3 Variants in Breast Cancer Metastasis awarded by Susan G. Komen Breast Cancer Foundation, Inc. Key Personnel 2017 - 2020

more ...

less ...

Background

education and training

M.B.A., Massachusetts Institute of Technology 2014
M.D., Mount Sinai School of Medicine 1987
B.A., Barnard College - Columbia University 1982

Contact

full name

Linda T Vahdat

primary email

ltv2001@med.cornell.edu

VIVO Weill Cornell Medical College

Linda T Vahdat Professor of Medicine

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

Phone

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email